Baker Bros. Advisors LP Stoke Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

  • $9.86 Billion
  • Q2 2025

A detailed history of Baker Bros. Advisors LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 4,633,838 shares of STOK stock, worth $115 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares
4,633,838
Previous 4,633,838 -0.0%
Holding current value
$115 Million
Previous $30.8 Million 70.68%
% of portfolio
0.53%
Previous 0.37%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$10.8 - $13.92 $2.87 Million - $3.69 Million
265,395 Added 6.08%
4,633,838 $51.1 Million
Q2 2024

Aug 14, 2024
BUY
$11.03 - $17.52 $11 Million - $17.5 Million
1,000,000 Added 29.69%
4,368,443 $59 Million
Q1 2024

May 15, 2024
BUY
$4.12 - $14.17 $5.51 Million - $19 Million
1,338,309 Added 65.92%
3,368,443 $45.5 Million
Q4 2023

Feb 14, 2024
BUY
$3.37 - $5.4 $1.83 Million - $2.94 Million
544,219 Added 36.63%
2,030,134 $10.7 Million
Q3 2023

Nov 14, 2023
SELL
$3.78 - $11.99 $2.44 Million - $7.73 Million
-644,323 Reduced 30.25%
1,485,915 $5.85 Million
Q2 2023

Aug 14, 2023
BUY
$7.93 - $13.82 $117,538 - $204,840
14,822 Added 0.7%
2,130,238 $22.6 Million
Q1 2023

May 15, 2023
BUY
$7.65 - $10.38 $7.7 Million - $10.4 Million
1,006,503 Added 90.76%
2,115,416 $17.6 Million
Q4 2022

Feb 14, 2023
BUY
$7.07 - $15.69 $5.23 Million - $11.6 Million
739,586 Added 200.25%
1,108,913 $10.2 Million
Q3 2022

Nov 14, 2022
BUY
$12.56 - $22.53 $4.64 Million - $8.32 Million
369,327 New
369,327 $4.74 Million

About Stoke Therapeutics, Inc.

STOK Quotes by TradingView
  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $978M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email